In a new in-depth article Michele Romano, PhD, responsible at BÜHLMANN for the Product Management of the CAST® Assays for Basophil Activation Tests (BAT), writes about the benefits of using BAT assays in drug discovery and preclinical evaluation of kinase inhibitors.
- info@buhlmannlabs.ch
- +41 61 487 12 12
Tag Archives: basophil activation test
Flow CAST® – Kinase Inhibtion Assay Citation: Matthews, D.J. et al. Discovery of PI3K delta inhibitors for the treatment of inflammatory and autoimmune disease. 2012 New York Academy of Sciences Meeting Poster. "Importantly, PWT143 inhibits basophil activation (as measured by surface CD63 expression in a whole blood assay) with subnanomolar potency in response to anti-IgE stimulation
Continue Reading →
Flow CAST® – Kinase Inhibtion Assay Citation: VakkalankaS. et al. TGR-1202 suppresses acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cells via selective inhibition of PI3Kδ kinase. 2012 ASH Meeting Poster. "TGR-1202 demonstrated significant potency against PI3Kδ (22.2 nM) with several fold selectivity over the α (>10000), β (>50), and γ (>48) isoforms. Additionally, the
Continue Reading →
Flow CAST® – Kinase Inhibtion Assay Citation: Advani, R.H. et al. Brutontyrosine kinase inhibitor ibrutinib(PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J ClinOncol. 2013 Jan 1; 31(1): 88-94. PMID: 23045577 "A decrease in anti–IgE-stimulated basophil degranulation was observed, consistent with the role of BTK downstream of the high-affinity IgE receptor."
Continue Reading →
Social Links